Staging of Superficial EAC Using VLE


About this study

This study is being done to see if the NvisionVLE Imaging System can accurately determine the diagnostic performance of staging of T1 esophageal adenocarcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patient over the age of 18
  • Patient undergoing an upper endoscopy with prior-biopsy confirmed Barrett's Esophagus.
  • Ability to provide written, informed consent
  • No significant esophagitis (LA grade

Exclusion Criteria:

  • Patients who have achieved complete remission of intestinal metaplasia (CR-IM)
  • Patients without visible Barrett's Esophagus at the time of study esophagogastroduodenoscopy (EGD)
  • Patients for whom use of the NvisionVLE device would be in conflict with the instruction for use.
  • Prior esophageal or gastric surgical resection
  • Significant esophageal stricture requiring dilatation
  • Patients who require anticoagulation for who biopsy would be contraindicated
  • Patients who are known to be pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Cadman Leggett, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer